1. Home
  2. Companies
  3. LDX
  4. Material Events

Lumos Diagnostics (ASX:LDX) — Material Events

ASX:LDX · 22 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 2 articles Significant 15 articles Notable 5 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
15
Lumos Diagnostics Powers Ahead with FebriDx® Sales and FDA MilestonesMedium
Lumos Diagnostics Q2 FY26: FebriDx® sales surge, FDA CLIA waiver on track, full Medicare coverage secured
29 Jan 2026 ·Quarterly Activity Statement and Appendix 4C ·85
Lumos Diagnostics Secures US$317M Deal, Awaits FDA Nod on FebriDx®High
Lumos Diagnostics Signs US$317M Distribution Deal, Advances FebriDx® FDA Submission and Pediatric Study
23 Oct 2025 ·Quarterly Activity Statement and Appendix 4C Cash Flow Report ·85
Lumos Clinches Full Medicare Reimbursement for FebriDx Across All US RegionsMedium
Lumos Secures Full U.S. Medicare Reimbursement for FebriDx Test
21 Nov 2025 ·ASX Announcement ·85
Lumos Diagnostics Lands US$1.3M FebriDx® Order After FDA BoostMedium
Lumos Diagnostics secures largest FebriDx® order post FDA clearance, valued at US$1.3 million
1 Apr 2026 ·ASX Announcement ·85
Lumos Diagnostics Expands US Market with FDA CLIA Waiver, Triggers US$6.2M MilestonesHigh
Lumos Diagnostics secures FDA CLIA waiver for FebriDx®, triggers US$6.2M milestone payments, reports 37% revenue growth in Q3 FY26
20 Apr 2026 ·Quarterly Activity Statement and Appendix 4C Cash Flow Report ·85
Lumos Advances Paediatric Study, Secures US$720K Milestone PaymentMedium
Lumos hits paediatric study milestone, earns US$720K payment, advancing FebriDx® FDA expansion
23 Feb 2026 ·Milestone Payment Announcement ·85
Lumos Secures A$5 Million Loan to Fuel FebriDx® US PushHigh
Lumos secures A$5 million loan facility to support FebriDx® CLIA waiver and US commercialization
17 July 2025 ·Capital Raising ·85
Lumos Diagnostics’ Loss Widens as FebriDx Secures Major US Distribution DealHigh
Lumos Diagnostics reports widening half-year loss amid strong FebriDx progress and major US distribution deal
27 Feb 2026 ·Appendix 4D Half-year report ·85
Lumos and BARDA Launch $6.2M Pediatric Study to Expand FebriDx Use in USMedium
Lumos and BARDA launch $6.2M pediatric FebriDx® study to expand U.S. market
1 Sept 2025 ·ASX Announcement ·85
Lumos Diagnostics Secures US$317M Deal as FebriDx Nears FDA MilestoneHigh
Lumos Diagnostics reports FY25 revenue growth, secures US$317M FebriDx distribution deal, advances FDA CLIA waiver study
21 July 2025 ·Quarterly Activity Statement and Appendix 4C Cash Flow Report ·85
Lumos Diagnostics Seeks FDA CLIA Waiver, Unlocking $2.75M Milestones and $1B MarketMedium
Lumos Diagnostics submits FDA CLIA waiver application for FebriDx®, unlocking $2.75M in milestones and expanding U.S. market potential
18 Aug 2025 ·Regulatory Submission Announcement ·80
Lumos Diagnostics Resumes Trading After Strategic Deal AnnouncementMedium
Lumos Diagnostics reinstated to ASX trading after strategic agreement announcement
16 July 2025 ·Reinstatement to Quotation ·80
Lumos Diagnostics Hits 250 Patient Milestone in Paediatric FebriDx StudyMedium
Lumos Diagnostics hits 250 patient enrolment milestone in BARDA-funded FebriDx paediatric study, earning US$670K payment
14 May 2026 ·Milestone Achievement Announcement ·75
Lumos Lands $1.5M Contract to Advance PKU Home Monitoring DeviceMedium
Lumos secures US$1.5M follow-on contract with Aptatek for PKU in-home monitoring device development
1 Sept 2025 ·Contract Announcement ·75
Lumos Diagnostics Reports Strong Early Reimbursement for FebriDx in US RolloutMedium
Lumos reports positive early U.S. rollout and reimbursement progress for FebriDx test
18 May 2026 ·Commercial Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.